News | Stem Cell Therapies | May 12, 2017

Stem Cell Therapy Holds Promise for Treating Most Severe Cases of Angina

Meta-analysis shows CD34+ stem cells reduce mortality for Class III and IV refractory angina patients

Stem Cell Therapy Holds Promise for Treating Most Severe Cases of Angina

May 12, 2017 — An analysis of data from the entire development program consisting of three trials assessing the feasibility of using a stem cell therapy (CD34+ cells) to treat patients with refractory angina showed a statistically significant improvement in exercise time as well as a reduction in mortality. Results from “CD34+ Stem Cell Therapy Improves Exercise Time and Mortality in Refractory Angina: A Patient Level Meta-Analysis” were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions, May 10-13 in New Orleans.

One of the warning signs of coronary artery disease is angina, or chest pain, which occurs when the heart muscle does not receive enough blood. Unlike angina pectoris or “stable angina,” which can often be treated with medication, refractory angina (RA), the most severe case, can be incapacitating, impacting quality of life. In the most severe cases, those with class III or IV angina, treatment options are exhausted, and patients remain severely debilitated. Unfortunately, one of the untoward consequences of the improved survival of patients with chronic ischemic heart disease is more patients with refractory angina.

A meta-analysis of three trials that each showed promising results looked at injecting RA patients with autologous CD34+ cells — which have been shown to increase blood flow — and the therapy’s effect on mortality and total exercise time (TET), an important predictor of long-term mortality.

Data from 304 patients was extracted and analyzed from phase 1 (24 patients), ACT-34 and ACT-34 extension studies (168 patients), and RENEW (112 patients), which was prematurely terminated by the sponsor due to financial considerations.

“The goal of this meta-analysis was to combine patient-level data from three very similar trials to try understand what it would tell us,” said lead investigator Tom Povsic, M.D., FSCAI, associate professor at the Duke Clinical Research Institute (DCRI) and an interventional cardiologist at Duke University School of Medicine.

Results showed that patients treated with CD34+ cell therapy (n=187) improved TET by 80.5 ± 12.1, 101.8 ±13.7, and 90.5 ± 14.7 seconds at three months, six months and 12 months compared with 28.1 ± 15.7, 48.8 ± 18.2, and 39.5 ± 20.3 seconds for the placebo group (n=89); this resulted in treatment effects of 52.5 (p=0.002), 52.9 (p=0.009) and 50.9 (p=0.027) seconds.

The relative risk of angina was 0.90 (p=0.40), 0.81 (p=0.14) and 0.79 (p=0.17) at three months, six months and 12 months in CD34+ treated patients.

CD34+ treatment decreased mortality by 24 months (2.6 percent vs. 11.8 percent, p=0.003). In addition, major adverse cardiac events were less frequent (29.8 percent for CD34+ patients versus 40 percent for the placebo group, p=0.08).

“Therapies for these patients are direly needed,” said Povsic, “and results from our meta-analysis are very compelling. Most importantly, the number of patients in our meta-analysis approximates those who were targeted for enrollment in RENEW, the prematurely terminated phase III study. These results suggest that had RENEW been completed, a regenerative therapy for these patients might meet criteria for approval. I still think this therapy has a lot of promise.”

Timothy Henry, M.D., chief of cardiology at Cedars-Sinai Medical Center in Los Angeles, agreed. “CD34+ cell therapy appears to be an extremely safe and effective therapy for this growing and challenging patient population with limited options,” he said.

Povsic reported no disclosures.

Related Content About Stem Cell Therapies to Restore Heart Function

FDA Says Adult Stem Cell Research Shows Promise

3-D Printed Patch Can Help Mend "Broken" Heart

Cardiac Regeneration After MI: Role of the Extracellular Matrix

Post Heart Attack Recovery Not Aided By Stem Cell Injections, But Demonstrates Promise

Resurrecting Dead Heart Tissue

 

For more information: www.scaiscientificsessions.org

Related Content

ECG Study of NBA Players Shows Need for Sport-Specific Normative Data and Guidelines
News | ECG| December 08, 2017
Cardiologists at NewYork-Presbyterian/Columbia University Irving Medical Center compared electrocardiographic findings...
New Study Suggests Protein Could Protect Against Coronary Artery Disease

Patients with no obstructed blood flow in the coronary arteries had higher levels of CXCL5 (blue) compared to patients with moderate levels (green) or lower levels (yellow) of CXCL5, who had increased severity of coronary obstructions (indicated by the arrows). Credit: Schisler lab

News | Cardiac Diagnostics| December 07, 2017
December 7, 2017 — The buildup of plaque in the heart’s arteries is an unfortunate part of aging.
New Tool Predicts Risk of Heart Attack in Older Surgery Patients
News | Cardiac Diagnostics| December 05, 2017
A tool designed to more accurately predict the risk of heart attack in older patients undergoing non-cardiac surgery...
Screening for Critical Congenital Heart Disease at Birth Saves Lives
News | Congenital Heart| December 05, 2017
Infant deaths from critical congenital heart disease (CCHD) decreased more than 33 percent in eight states that...
Philips Azurion Platform Improves Clinical Workflow and Staff Experience Benefits
News | Angiography| December 04, 2017
Philips recently announced the results of a comprehensive, independent, two-year study demonstrating the clinical...
Sudden Cardiac Arrest Seven Times Higher Among Younger Diabetics. Zoll
News | November 25, 2017
November 25, 2017 — Children and young adults with diabetes may be seven times more likely to die from sudden cardiac
Coffee Associated With Reduced Risk of Heart Failure, Stroke. AHA 2017. #AHA2017
News | Heart Failure| November 25, 2017
November 25, 2017 — Drinking coffee may be associated with a decreased risk of developing heart failure or having str
2017 American Heart Association (AHA) annual meeting. AHA 2017, #AHA2017
Feature | November 25, 2017 | Dave Fornell
November 25, 2017 — Here is a list of some of the key clinical trial presentations at the 2017 American Heart Associa
Research team (left to right) Abdul Wase M.D. (principal ivestigator), Marina Brown R.N., Ken Shneider, Thein Aung M.D., Matt Clark, Dawn Hunt and Kimberle Evans R.N., with a Tesla car at Good Samaritan Hospital Dayton, Ohio.  Image courtesy of Joe Carfora.

Research team (left to right) Abdul Wase M.D. (principal ivestigator), Marina Brown R.N., Ken Shneider, Thein Aung M.D., Matt Clark, Dawn Hunt and Kimberle Evans R.N., with a Tesla car at Good Samaritan Hospital Dayton, Ohio. 
Image courtesy of Joe Carfora.

News | November 25, 2017
November 25, 2017 — Sitting in, or standing close to the charging port of a Tesla electric vehicle did not trigger a
Studies find 15 percent of all heart attack and stroke patients and 9 percent of CABG patients were uninsured before passage of the Affordable Care Act. AHA 2017, #aha2017
News | November 25, 2017
November 25, 2017 — The majority of patients without health insurance who were hospitalized for heart attack, stroke
Overlay Init